After Advanz’s £100m fine over the price of its thyroid tablets, two people recount the difficulty of obtaining medication
The UK’s competition watchdog has fined pharmaceutical company Advanz over £100m for inflating the price of its thyroid tablets by up to 6,000%. The exorbitant costs resulted in NHS clinical commissioning groups advising doctors not to prescribe liothyronine, locking out many people who depended on the tablets to alleviate the symptoms of hypothyroidism.
Related: Pharma firm Advanz fined after thyroid drug price hike of 6,000%
Related: UK drug companies fined £260m for inflating prices for NHS
